Brown Advisory Inc. Purchases 10,542 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Brown Advisory Inc. lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 80.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 23,718 shares of the medical equipment provider’s stock after buying an additional 10,542 shares during the period. Brown Advisory Inc.’s holdings in Zimmer Biomet were worth $2,163,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Resona Asset Management Co. Ltd. increased its position in shares of Zimmer Biomet by 5.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock worth $6,197,000 after purchasing an additional 3,634 shares in the last quarter. QSM Asset Management Ltd raised its stake in Zimmer Biomet by 36.1% in the second quarter. QSM Asset Management Ltd now owns 111,500 shares of the medical equipment provider’s stock valued at $10,174,000 after buying an additional 29,600 shares during the last quarter. Truist Financial Corp boosted its holdings in Zimmer Biomet by 34.4% in the second quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock worth $2,446,000 after acquiring an additional 6,867 shares in the last quarter. Magellan Asset Management Ltd boosted its holdings in Zimmer Biomet by 16.8% in the second quarter. Magellan Asset Management Ltd now owns 505,901 shares of the medical equipment provider’s stock worth $46,143,000 after acquiring an additional 72,613 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its stake in shares of Zimmer Biomet by 89.8% during the second quarter. State of Alaska Department of Revenue now owns 44,261 shares of the medical equipment provider’s stock worth $4,036,000 after acquiring an additional 20,945 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.4%

NYSE ZBH opened at $92.37 on Wednesday. The company has a fifty day moving average of $96.07 and a 200 day moving average of $96.76. The company has a market capitalization of $18.31 billion, a PE ratio of 22.86, a P/E/G ratio of 2.44 and a beta of 0.61. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. Zimmer Biomet Holdings, Inc. has a 1 year low of $85.33 and a 1 year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same quarter last year, the business posted $1.74 EPS. The company’s revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Evercore ISI decreased their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $100.00 price objective (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Stifel Nicolaus set a $110.00 price objective on shares of Zimmer Biomet in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Finally, Johnson Rice set a $112.00 price target on Zimmer Biomet in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $109.00.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.